
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): September 8, 2017

Codexis, Inc.

(Exact name of Registrant as Specified in its Charter)

Delaware
(State or other jurisdiction
of incorporation)

001-34705
(Commission
File Number)

71-0872999
(I.R.S. Employer
Identification No.)

200 Penobscot Drive
Redwood City, CA 94063
(Address of Principal Executive Offices) (Zip Code)

(650) 421-8100
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

On September 8, 2017, Codexis, Inc. (the “Company”) updated its corporate presentation (the “Corporate Presentation”) in connection with upcoming investor conferences. A copy of the Corporate Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated by reference herein.

The information furnished in this Current Report on Form 8-K pursuant to Item 7.01 (including Exhibit 99.1) shall not be deemed to be “filed” under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.

Item 9.01 Financial Statements and Exhibits.**(d) Exhibits.**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Corporate presentation of Codexis, Inc.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 8, 2017

CODEXIS, INC.

By: /s/ Gordon Sangster

Name: Gordon Sangster

Title: Senior Vice President and Chief Financial Officer

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Exhibit Description</u>
99.1	<u>Corporate presentation of Codexis, Inc.</u>

Unlock the power of proteins™



CODEXIS®
PROTEIN ENGINEERING EXPERTS

September 2017

Codexis Corporate Presentation
Nasdaq: CDXS

Forward-Looking Statements


- These slides and the accompanying oral presentation contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” or the negative of these terms, and similar expressions and comparable terminology intended to identify forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
- Other factors that could materially affect actual results, levels of activity, performance or achievement can be found in Codexis’ Form 10-K for the period ended December 31, 2016 filed with the SEC on March 9, 2017 and Form 10-Q for the period ended June 30, 2017 filed with the SEC on August 9, 2017, including under the caption “Risk Factors.” If any of these risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results, levels of activity, performance or achievement may vary significantly from what we projected.
- Our logo, “Codexis,” “CodeEvolver,” and other trademarks or service marks of Codexis, Inc. appearing in this presentation are the property of Codexis, Inc. This presentation contains additional trade names, trademarks and service marks of other companies. We do not intend our use or display of other companies’ trade names, trademarks or service marks to imply relationships with, or endorsement or sponsorship of us by, these other companies.

Welcome to the Protein Revolution

CODEXIS[®]
PROTEIN ENGINEERING EXPERTS

Digital Revolution Genomics Revolution

— Digital Revolution Moore's Law
— Genomics Revolution




Complexity of Protein Structure - Function Relationships

DNA Code



Protein Structure




Infinitely
Complex

Protein Function



CODEXIS[®]
PROTEIN ENGINEERING EXPERTS

The Protein Revolution – Now Is the Time



Codexis – Leading The Protein Revolution



Company History
15+ Years



Cumulative Investments
> \$500m



Employees
~115 (65 in R&D)



Patents & Applications
> 900 worldwide




Protein Project Pipeline *
8 Proteins Commercialized
+ 25 Pre-Commercial (+44% y-o-y)




Growing Revenues
\$49m in 2016
18% CAGR since 2014

CODEXIS[®]
PROTEIN ENGINEERING EXPERTS

* Codexis Pipeline Snapshot as of June 30, 2017 (<https://goo.gl/DZ42Eo>)



Project Speed Driving Codexis Growth



CODEXIS[®]
PROTEIN ENGINEERING EXPERTS

A Growing List of Markets Served



Productivity Improvements Reduce CAPEX



CHALLENGE

Capacity constraints in existing supply chain



SOLUTION

- From zero activity to commercial targets in <12 months
- 53% higher productivity
- 19% reduction in energy usage
- Expensive, toxic chemo-catalyst replaced
- No new factory needed

“...[Codexis] helped avoid the cost of building a 2nd factory to meet the rising demand for Januvia.®”
Skip Volante, Merck VP R&D

CODEXIS[®]
PROTEIN ENGINEERING EXPERTS

CodeEvolver® Licensing Creates Value Across Portfolio



CHALLENGE

How to effectively leverage protein engineering to improve GSK's portfolio?



SOLUTION

- Licensed the CodeEvolver® platform
- Deeply embedded the technology in house
- Applications from discovery to post launch
- Codexis earns front end and back end economics
- Partnership created around shared vision for proteins and mutual success of CodeEvolver®

"We chose the Codexis platform after a thorough evaluation of the enzyme evolution landscape..."
Doug Fuerst, GSK Technology Development Lead, Synthetic Biology

CODEXIS®
PROTEIN ENGINEERING EXPERTS

Rapid Product Launch Enabled by Cost-Efficient Process



CHALLENGE

Healthier food ingredient requires a lower cost process to enable the product launch



SOLUTION

- Commercial targets met in 7 months
- 20-fold catalyst stability improvement
- 90+% reduction in catalyst system cost
- Enabled commercial production of the healthy ingredient < 2 years after 1st project discussion

"We view Codexis as an extension of our internal R&D programs at Tate & Lyle..."

Michael Harrison, Tate & Lyle SVP, New Product Development

CODEXIS[®]
PROTEIN ENGINEERING EXPERTS

Therapeutic Enzyme to Treat Phenylketonuria (PKU)



In the USA ~1:15,000 newborns have PKU, causing lifelong neurocognitive symptoms



CHALLENGE

Besides aggressive dietary control, no available treatment for > 80% of PKU patients



SOLUTION

- First CodeEvolver® drug discovery breakthrough
- Stability in GI tract enables convenient oral dosage
- > 50-fold stability improvement, *in vitro*
- Efficacy demonstrated in four preclinical models
- Human trials targeted to start in early 2018

CODEXIS[®]
PROTEIN ENGINEERING EXPERTS

“Many individuals with PKU are eagerly awaiting new therapeutic options. CDX-6114 holds the potential of being an attractive treatment for PKU.”

Dr. Gregory Enns, Professor of Pediatrics, Division of Medical Genetics, Stanford University Hospital

Improving Sensitivity and Precision in Molecular Diagnostics



Detecting cancer has historically required invasive tissue biopsy



CHALLENGE

Create more sensitive, fluid-based diagnostic tests: earlier, less invasive cancer detection



SOLUTION

- Codexis engineered enzymes for next gen sequencing with greater sensitivity and precision
- Detection of very, very low concentrations of target DNA in blood
- Dependable test results without tissue biopsies
- Ability to tailor enzyme performance to specific sample or test conditions

CODEXIS[®]
PROTEIN ENGINEERING EXPERTS


Codexis' first product offerings to customers who are already using others' enzymes.
Simpler sales process enables even faster time to Codexis product commercialization.

Codexis: Monetizing The Protein Revolution


Proven Revenue Generation & Partnering Approaches



Growing R&D Revenues



Growing Product Revenue and Expanding Margins



* 2017 Guidance Range Provided on August 9, 2017



Growing List of Major Partnerships Driving Growth

Partner	Type of Partnering Deal	2014	2015	2016	2017	2018+
GSK	CodeEvolver® Platform	\$6.0m	\$14.5m	\$22.5m		\$25m+
Merck	CodeEvolver® Platform					
T&L (March '17 Deal)	Major Product (Food Ingredient) Target				-\$10m	
2H'17 New Partner						
Another New Major Partner						
# Major Partners Generating Revenues		1	2	2	2	4+



Codexis Biotherapeutics Pipeline

CodeEvolver® Generated *in vitro*
Candidate Discovery

Preclinical Research

IND Enabling

Human Trials

PKU CDX-6114

Drug Target 1 (DT1)

DT2

DT3

DT4


Step-out Opportunities from
Monetizing Biotherapeutics Pipeline

CODEXIS[®]
PROTEIN ENGINEERING EXPERTS

20



Consistently Growing Total Revenues



Codexis Investment Summary



Protein Revolution Leadership

- \$500+ million invested over 15+ years
- Every project adds to CodeEvolver® knowledge base and enhances value



Deep Relationships with Industry Leaders

- Multiple revenue streams validate the CodeEvolver® technology platform
- Further upside in molecular diagnostics, therapeutics, and new verticals



Strong Financial Momentum

- Forecasted 2017 revenues of \$50-\$53 million
- Includes >\$25 million product sales, more than doubled over past 2 years



Clean, Sufficient Balance Sheet

- \$28.8 million as of June 30, 2017

Corporate Headquarters

200 Penobscot Drive
Redwood City, CA 94063
USA



John Nicols

President & Chief Executive Officer

- john.nicols@codexis.com
- (650) 421-2388

Gordon Sangster

Senior Vice President & Chief Financial Officer

- gordon.sangster@codexis.com
- (650) 421-8115

Jody Cain

Lippert Heilshorn & Associates

- Codexis Investor Relations Partner
- jcain@lhai.com
- (310) 691-7100